Epidemiology of Microsatellite Instability High (MSI-H) and Deficient Mismatch Repair (dMMR) in Solid Tumors: A Structured Literature Review

Table 1

Eligibility criteria.

Criteria	Description
Population	Patients with solid tumors
Outcomes	(i) Assessment of prevalence of MSI-H (using NCI marker panel: BAT25, BAT26, D2S123, D5S346, and D17S250) or Promega marker panel: BAT25, BAT26, NR21, NR24, and MONO27) and/or dMMR (by immunohistochemistry for all four MMR proteins: MLH1, MSH2, MSH6, and PMS2) overall, by tumor type, by histology subtype, by stage, by treatment, by region, by country, and by gender
	(a) Proportion of MSI as defined in study (e.g., MSI-H, MSI-L, and MSI-S)
	(b) Proportion of dMMR and pMMR as defined in study
	(ii) Survival rates by MSI-H/dMMR status overall, by stage and by tumor type
	(a) Overall survival (OS) and progression-free survival (PFS)
	(1) Hazard ratios along with 95% confidence interval (CI)
	(2) Median (in months) and 95% CI
	(iii) Objective response rate (ORR), defined as complete response (CR) or partial response (PR)
	(iv) Disease control rate, defined as CR, PR, or stable disease
Study design	(i) Prospective and retrospective cohort studies
	(ii) Randomized controlled trials
	(iii) Case-control studies
	(iv) Cross-sectional studies
	(v) Controlled and uncontrolled longitudinal studies (cohorts or case series)
Language	Only studies published in English will be included
Time	No time limit

Abbreviations: dMMR, deficient mismatch repair; MLH1, MutL homolog 1; MSH2, MutS protein homolog 2; MSH6, MutS homolog 6; MSI-H, microsatellite instability high; MSI-L, microsatellite instability low; MSI-S/MSS, microsatellite stable; NCI, National Cancer Institute; pMMR, proficient mismatch repair; PMS2, postmeiotic segregation increased 2.